mavrilimumab
mAbexperimental
Mavrilimumab is a human monoclonal antibody that inhibits human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R). — Wikipedia
Clinical trial activity
13 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
10
Phase 3
1
Phase 4
0
Earliest trial started Oct 1, 2008 (NCT00771420)
Timeline
Indications
Mechanism of action
CSF2 antagonist
Granulocyte-macrophage colony-stimulating factor receptor antagonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMavrilimumab ↗
- ChEMBLCHEMBL1743039 ↗
Also known as
- cam-3001
- cam-3001
- cam-3001
- mavrilimumab
- mavrilimumab
- mavrilimumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04463004 | Phase 2 | Sep 2, 2020 | Kiniksa Pharmaceuticals, Ltd., Virginia Commonwealth University |
| NCT04447469 | Phase 2/Phase 3 (Phase 3) | Jul 27, 2020 | Kiniksa Pharmaceuticals, Ltd. |
| NCT04337216 | Phase 2 | May 31, 2020 | Virginia Commonwealth University |
| NCT04397497 | Phase 2 | May 22, 2020 | Vita-Salute University of Milano. Italy |
| NCT04492514 | Phase 2 | May 20, 2020 | Kiniksa Pharmaceuticals, Ltd., University of Cincinnati |
| NCT04399980 | Phase 2 | May 20, 2020 | Kiniksa Pharmaceuticals, Ltd., The Cleveland Clinic |
| NCT03827018 | Phase 2 | Dec 21, 2018 | Kiniksa Pharmaceuticals, Ltd. |
| NCT02213315 | Phase 1 | Jul 1, 2014 | Hammersmith Medicines Research, MedImmune |
| NCT01715896 | Phase 2 | Mar 1, 2013 | MedImmune |
| NCT01712399 | Phase 2 | Jan 28, 2013 | MedImmune |
| NCT01706926 | Phase 2 | Aug 1, 2012 | MedImmune |
| NCT01050998 | Phase 2 | Jan 1, 2010 | MedImmune |
| NCT00771420 | Phase 1 | Oct 1, 2008 | MedImmune |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MedImmune | For profit | 6 | 6 | 2 | 2008 |
| Kiniksa Pharmaceuticals, Ltd. | For profit | 5 | 2 | 2 | 2018 |
| Virginia Commonwealth University | Academic/Hospital | 2 | 2 | 1 | 2020 |
| Hammersmith Medicines Research | For profit | 1 | 0 | 1 | 2014 |
| The Cleveland Clinic | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Cincinnati | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Vita-Salute University of Milano. Italy | Academic/Hospital | 1 | 1 | 1 | 2020 |
7 organizations
Page 1 / 1